Case Study 2 — The Practice That Became a Supplier: A Composite

Constructed. The practice and the figures are not real. The pattern — a clinical practice acquiring a regulatory identity it did not know it had acquired — is ordinary, and DMEPOS carries among the highest documented improper payment rates of any category in this book.

Background

Section 20.5 ended a paragraph with a sentence that sounds like an aside:

A physician practice that dispenses a brace has become a supplier, with everything that implies, and practices frequently discover this after the fact.

"Everything that implies" is a great deal, and this is a practice that found out in the usual way.

The composite

Constructed.

An orthopedic practice. Well run, clinically strong, and — like most orthopedic practices — routinely sending patients home in braces.

For years, the braces came from an outside supplier. The practice wrote a prescription, the patient went elsewhere, and the practice had nothing to do with the transaction.

Then the practice began stocking braces itself.

The reasoning was good and it was clinical: patients were leaving without their braces, or getting the wrong size, or not going at all. Stocking a handful of common items and fitting them in the office solved a real problem for real patients, and it did.

Nobody in the conversation was thinking about enrollment.

What had actually happened

The practice had become a DMEPOS supplier.

That is a regulatory status, not a description. It carries:

Separate enrollment, with its own application, its own supplier number, and its own approval process.

Supplier standards — a defined list of operational requirements covering hours, signage, telephone access, complaint records, product liability insurance, and more. They are a checklist and they are verified.

Surety bond requirements in many circumstances.

Accreditation requirements for many item categories.

And an entirely different documentation regime — §20.5's written order, the medical record supporting need independently, delivery documentation, proof-of-delivery retention, and item-specific requirements on top of all of it.

The practice had none of it, because nothing about stocking a brace announces that you have entered a different regulatory world.

How it surfaced

Claims paid for about eighteen months. (Constructed.)

Then a supplier audit — routine, of the kind this category receives more of than any other — requested documentation for a sample of items.

The findings, in the order they were reported:

Orders were present. The practice's physicians had written orders and the orders were in the file. This surprised nobody; the practice was conscientious.

The medical records did not independently support medical necessity for a majority of the sampled items. The notes said the brace was provided. They did not say why this patient needed this item, in the terms the item's policy required.

Proof of delivery was inconsistent. Some items had it, some had a note that the item was dispensed, some had neither.

And several supplier standards were not met, including some that are purely operational and have nothing to do with clinical care.

The part that should worry you

The braces were medically appropriate.

Nobody in the audit suggested otherwise. The patients had the injuries. The braces were the right braces. The physicians were right about the clinical question and the practice was right that patients were better off getting the brace in the office.

And essentially none of it was payable, because in this category the documentation is not evidence of the qualification. It IS the qualification.

§20.5 said that in a compliance callout and it is worth repeating with the case attached: an item can be genuinely needed, genuinely delivered, correctly fitted, and entirely unpayable, and the reason is not that anyone doubts the need. It is that the policy specifies which facts must be in the record, and they are not.

What it cost

(Constructed.) Repayment of the sampled claims and, by extrapolation, of the population — Chapter 15 §15.12 described extrapolation and this is what it looks like in a category with a high error rate.

Plus the cost of coming into compliance: enrollment, accreditation for the categories the practice intended to continue, a surety bond, operational changes to meet the supplier standards, and a documentation template built around each item's policy requirements.

The practice's decision, in the end, was to keep doing it. (Constructed.) Patients genuinely were better served, and the practice concluded that the fixed costs were worth it at their volume.

A smaller practice would have stopped, and that is the part worth noticing: the compliance overhead is largely fixed, which means the same activity is viable at one scale and not at another — for reasons that have nothing to do with whether patients are well served.

What it shows

First, an organization can acquire a regulatory identity without deciding to. Nobody voted to become a DMEPOS supplier. A clinical improvement was implemented and a regulatory status came with it, unannounced. This is worth generalizing: any time an organization starts doing something new, the question "what have we now become, for regulatory purposes?" has an answer, and usually nobody asks.

Second, "the physicians were right" is not a defense in this category. It is the hardest thing about DMEPOS and it is why the improper payment rates are what they are. Clinical correctness and payability are different questions, and in most of this book they run together closely enough that people forget they are different. Here they come apart completely.

Third, the remedy is a list, not an exhortation. §20.5 said it: read the policy for this item, find the facts it requires, and put that list in front of the clinician. "Document better" would have achieved nothing here. A template with the six specific facts the policy names would have achieved everything.

Fourth, the fixed-cost structure decides who can do this. Enrollment, accreditation, bonding, and standards do not scale down. A practice that would serve its patients better by stocking items may rationally decline to, and whether that is a good outcome is a real policy question rather than a rhetorical one.

And fifth — this is the fourth chapter in a row where the failure was invisible from inside. The practice could not see it because nothing about dispensing a brace signals a change in status, and because claims paid for eighteen months. Chapter 14's Case Study 2 established that a paid claim is not a verified claim. Eighteen months of payment is not eighteen months of evidence.

The lesson

When you start doing something new, ask what you have become. The answer is frequently "a regulated entity," and nothing will tell you.

Four carry-forwards:

Before dispensing anything, find out what enrollment it requires. One question, asked in advance, to someone who knows. It is the cheapest moment in this entire composite.

Get the item's policy and extract the required facts into a template. Not a documentation reminder — the actual list of facts, in the note, as fields.

Keep proof of delivery, consistently, from the first item. It is trivial to do from day one and impossible to reconstruct.

And treat eighteen months of clean payment as no evidence of anything. By this point in the book that should be reflexive.

Discussion questions

1. Nobody decided to become a DMEPOS supplier. Design the trigger that would have caught it. What event fires it, and who receives it?

2. The braces were medically appropriate and largely unpayable. Is that a reasonable system design? Argue the policy's side, then say what you would change.

3. The compliance overhead is largely fixed. What does that imply about which practices can offer in-office dispensing, and is that outcome intended?

4. §20.5 says "read the policy, find the required facts, put the list in front of the clinician." Pick any item you know and try it. What is hard about this in practice?

5. Four consecutive chapters have featured failures invisible from inside the organization. Is the book overstating this, or is invisibility genuinely the defining property of revenue cycle failure? Take a position.